Strides Shasun’s top line has been boosted in Q4FY16

Strides Shasun has declared its fourth quarterly results on May 16. The company’s revenue has increased by 17.85 per cent to Rs 1002 crore in Q4FY16 as compared to previous quarter. Its EBITDA also has risen by 22.56 per cent to Rs 190 crore in Q4FY16 on a quarterly basis. Strides Shasun’s EBITDA margin has expanded by 72 basis points to 18.92 per cent in Q4FY16 as compared to previous quarter. The company’s Net profit has increased by 63.61 per cent to Rs 96 crore in Q4FY16 on a sequential basis. Its Net Profit margin has expanded by 262 basis points to 9.6 per cent in Q4FY16 on a quarterly basis.

On a yearly basis, Strides Shasun’s revenue has increased by 43 per cent to Rs 10036 crore in Q4FY16 on a yearly basis. The company’s EBITDA has risen by 61 per cent to Rs 2016 crore in Q4FY16 as compared to same period in previous financial year.

Strides Shasun’s top line has increased by 25 per cent to Rs 3178 crore in FY16 as compared to previous financial year. The company’s EBITDA too has risen by 43 per cent to Rs 5617 crore in FY16 on a yearly basis. Its EBITDA margin has expanded by 230 basis points to 18 per cent in FY16 as compared to previous fiscal year. Strides Shasun has posted PAT at Rs 2468 crore in FY16.

The share price of Strides Shasun has increased by 1.46 per cent on bourses in early trades; and is trading at Rs 1171.15 on an intraday basis.

Strides Shasun is a vertically integrated global pharmaceutical company headquartered in Bangalore. The company has four business verticals viz. Regulated Markets; Emerging Markets;Institutional Business; and Pharmaceutical Services & Active Ingredients. It has a global manufacturing foot-print with 14 manufacturing facilities spread across three continents including 6 USFDA approved facilities and 8 facilities for the emerging markets. Strides Shasun has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries.